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Does education influence the acceptability of faecal 
microbiota transplantation in colitis: A cross-
sectional study
Bret S. Palmer1*, Chris Metcalfe1, Aileen Fraser2 and Tom Creed2
Abstract: Objectives: Dysbiosis can have a profound effect on the health of the indi-
vidual and is considered to be a contributing factor to many health problems such 
as Inflammatory Bowel Disease and Clostridium difficile infection. Faecal Microbiota 
Transplantation (FMT) is potentially a safe method of renewing the ecology and 
correcting the dysbiosis, so alleviating the associated conditions. This study aims to 
identify any barriers to the acceptability of FMT in colitis patients and whether these 
barriers can be overcome through education. Methods: An unsolicited online survey 
distributed via Crohn’s and Colitis (CCUK) to approximately 900 members suffering 
from colitis. Results: 224 responses were received, a response rate of 25%. 36.2% 
(n = 81) of respondents were male. The age range of participants was 19–81 years 
(mean 45.1). After the demographic and medical status questions, participants were 
asked “Does FMT sound acceptable to you?” Out of the respondents that answered 
this question only 37.1% (n = 78, 43.2% of these being male) agreed with this state-
ment, with the remainder answering no (n = 40) or unsure (n = 92). After various 
questions and explanations examining the process of FMT, individuals were asked 
this question again with 53.6% (n = 105, 59.7% of these being male) stating that 
this procedure was now acceptable (p < 0.001). Conclusion: The acceptability of FMT 
was found to be low but can be improved with the provision of information.
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I have long been interested in the relationship 
and interplay between disease and microbes. 
My understanding of this relationship has 
changed from not just how pathogenic microbes 
cause disease but how we need a wide range 
of microbes to sustain good overall physical 
and mental health. While FMT is an unpleasant 
procedure it is one of the few methods of microbe 
replacement that has proven to be effective. If 
FMT remains the only effective method of microbe 
replacement, then understanding how to improve 
greater acceptability of this procedure will become 
key to limiting many non-communicable diseases, 
as well as reducing the burden of many diseases 
linked to a westernised life style.
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For the past four billion years a war has been 
going on between bacteria and viruses. This war 
has pushed forward the evolution of all other life 
including mankind. The conflict between bacteria 
and viruses continues within our gut today. It is 
this ecosystem which we have evolved with that 
helps keep us healthy. When our gut’s ecosystem 
becomes unbalanced it can lead to various diseases. 
It is thought that by transplanting a healthy 
ecosystem into an unhealthy person some disease 
processes such as Inflammatory Bowel Disease, 
metabolic syndrome and obesity could be reversed. 
In our study we examine the influence of education 
in the acceptability of transplanting a healthy 
ecosystem by faecal (stool) transplant and show 
that by explaining the science behind this treatment 
its acceptability is increased. With more diseases 
being linked to an unhealthy ecosystem, a greater 
understanding of this procedure is needed in society.
Received: 31 May 2016
Accepted: 05 September 2016
First Published: 16 September 2016
© 2016 The Author(s). This open access article is distributed under a Creative Commons Attribution 
(CC-BY) 4.0 license.
Page 1 of 23
Page 2 of 23
Palmer et al., Cogent Medicine (2016), 3: 1233685
http://dx.doi.org/10.1080/2331205X.2016.1233685
Subjects: Gastroenterology; General Medicine; Medicine
Keywords: faecal microbiota transplantation; acceptability; inflammatory bowel disease; 
microbiota
1. Introduction
The human bowel is home to 100 trillion bacteria and has an extensive, poorly understood, ecology 
(Lepage et al., 2013). It is now recognized that disruption within this ecology (dysbiosis) can have a 
profound effect on the health of the individual (Carding, Verbeke, Vipond, Corfe, & Owen, 2015). 
Dysbiosis is considered to be a contributing factor to many autoimmune diseases and is a common 
finding in many other wide ranging health problems such as obesity, asthma and metabolic syn-
drome (Carding et al., 2015).
Some autoimmune diseases have been known for centuries while others, such as Inflammatory 
Bowel Disease (IBD) and asthma have only been characterized in the last 100 years. The epidemiol-
ogy of autoimmune disease in the 20th century shows a steady increase in prevalence with diseases 
such as IBD becoming more common in countries which have transitioned to a more westernised 
culture with improved hygiene practices (Smith, Bloomfield, & Rook, 2012). For example IBD was 
largely unnoticed at the beginning of the 20th century; Crohn’s disease being formally discovered by 
Burrill Bernard Crohn in 1932, despite IBD being described in 1913 by Thomas Kennedy Dalziel (1913). 
However ulcerative colitis was described earlier by Samuel Wilks in 1859 but not confirmed until 
1931 by Sir Arthur Hurst (Hurst, 1931; Wilks, 1859). The current prevalence of IBD has now increased 
to 505 per 100,000 persons for ulcerative colitis and 322 per 100,000 persons for Crohn’s disease in 
Europe (Molodecky et al., 2012).
The annual cost of IBD for the NHS in England is approximately £1 billion, based on an average cost 
of £3,000 (US$4600, €4180) per patient per year (Bassi, Dodd, Williamson, & Bodger, 2004). This is 
likely to be an underestimate as it does not take into account the ever increasing drug costs due to 
the increased use of monoclonal antibodies, surgery and indirect costs to society, (UK Inflammatory 
Bowel Disease Audit 3rd Round, 2011) the burden of IBD in humans is increasing. As a result there has 
been renewed examination of fecal microbiota transplantation (FMT) as a possible method of treat-
ment. FMT is the process of taking feces from a healthy individual and transferring the feces into an 
unhealthy individual via NJ tube, colonoscopy or enema. The aim is to transplant a healthy gut eco-
system from a well individual to replace the unhealthy ecosystem in an individual affected by a dis-
ease which is thought to be amenable to this modality of treatment. While the evidence for FMT in 
treating pseudomembranous colitis due to Clostridium difficile is now robust as a second line treat-
ment, (NICE guidelines, 2014) the evidence for its use in IBD and ulcerative colitis (UC) in particular is 
at present patchy. One randomized trial investigating FMT in those with active UC, did induce remis-
sion in 24% of those who undertook FMT compared to 5% who took the placebo (Moayyedi et al., 
2015). Another small scale trial has reported no statistical difference in patients with UC treated with 
FMT, (Ponsioen, 2012; Rossen, Fuentes et al., 2015) other trials are completing in 2016 (Li, 2013; 
Marcus & Focht, 2013; Paramsothy, 2013). One meta-analysis did review 25 studies into Faecal 
Microbiota Transplantation (FMT) which showed FMT having a promising effect for UC (Shi et al., 2016). 
Another meta-analysis examining IBD showed a pooled subgroup analysis demonstrating a pooled 
estimate of clinical remission of 22% for UC and 60.5% for Crohn’s disease (Colman & Rubin, 2014) 
both meta-analysis suggests that FMT is safe. There are also many systematic reviews on FMT most 
have similar conclusions to that of the latest review we have found (Rossen et al., 2015) that FMT is 
highly effective in Clostridium difficile Infection and holds promise in UC. Even if these trials show posi-
tive outcomes and demonstrate FMT as an effective treatment for UC, there still remains the concern 
of acceptability. Many gastroenterologists do not consider FMT in the treatment of C. difficile as it is 
commonly assumed that a patient would find such a treatment to be unacceptable, despite the 
weight of evidence on its effectiveness (Zipursky, Sidorsky, Freedman, Sidorsky, & Kirkland, 2014). 
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To the best of our knowledge only one other study has investigated the acceptability of FMT in ulcera-
tive colitis patients, (Kahn et al., 2013) this study based in the United States of America had 95 partici-
pants with 46% of participants who were willing to undergo FMT.
This study reports a short descriptive analysis of the results from a survey taken by individuals with 
IBD who live in the South West of England, Great Britain, about their views on the acceptability of 
FMT, as a method of treatment for IBD. The aim of the study is to see if educating patients about the 
FMT procedure increases the acceptability of it.
2. Methods
A pilot questionnaire was constructed to ascertain the views of IBD sufferers on FMT as a treatment 
method. Questions were identified from validated IBD questionnaires. The pilot was trialed on 7 co-
litis patients at an IBD clinic at the Bristol Royal Infirmary. Patients were asked to answer the ques-
tions, how they felt about the nature of the questions, and their opinion of what else could have 
been asked or missed out. The results of the pilot were used to inform the final anonymous online 
questionnaire using Survey Monkey® (https://www.surveymonkey.com). The survey began with 
questions on basic demographic and medical data.
The survey then asked about respondents’ views on FMT and whether they felt it was an accept-
able method of treatment. A series of subsequent questions, structured around FMT, then gave re-
spondents more detailed information explaining the current theories, science and the FMT procedure 
(see the attached survey in Appendix 1). Finally, respondents were asked, knowing what they now 
know, would they consider receiving FMT. Respondents could not backtrack on previous answers 
submitted.
2.1. Study participants and recruitment
The population of interest was IBD sufferers within travelling distance of the Bristol area, as we 
wanted to gain a measure of acceptability of FMT in any future trial or service. Crohn’s and Colitis UK 
(CCUK) distributed the questionnaire, by prior agreement, to all of their members in Bristol and the 
surrounding areas, including South East Wales, UK. This totaled 900 Colitis members of the CCUK in 
December 2013. Participation was voluntary, and individuals could withdraw at any time during the 
questionnaire. Informed consent was obtained from each participant. Responses were treated 
anonymously and respondents were uncompensated for their time or expenses. An explanation of 
the survey was given to all participants with contact details if they had any remaining questions or 
concerns which they would like to be answered.
2.2. Ethical issues
This work was supported by the University of Bristol School of Social and Community Medicine and 
approved by the Faculty of Medicine and Dentistry Committee for Ethics, approval number: 4121 
(131403).
2.3. Analysis
Responses were collected over a period of three months. Differences in response on categorical meas-
ures between independent groups were tested for statistical significance using the χ2 test. The null 
hypothesis of no change in acceptability of FMT following information provision was tested using 
McNemar’s test, applied to the paired data from each participant’s two responses to this question 
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(questions 14 and 20 in the survey). In order to obtain a binary result the responses for “No” and “un-
sure” were added together. For question 8, on medications, there were no pre-specified hypothesis 
and so the data is not presented here. For Question 18 blood relatives were combined into a single 
response category, and no one chose the “friend” response category. The analysis in Tables 1 and 2 is 
based on responses obtained for questions 14 and 20 respectively.
Table 1. Responses obtained by the faecal microbiota transplantation questionnaire split by 
acceptability of FMT (Q14) before the provision of information
 Notes: P values were obtained by using the chi (c) square. Cells were combined to base the test on a 2x2 table, except 
where a 'baseline' is indicated, in which case we compared the other categories in turn to that baseline category. 
Where values are below five the Fisher's exact test was used.
aValues based on Chi square unless any values are under five then Fisher's exact test was used.
bValues on these columns are based on question 14.
Does FMT sound acceptable to you?b P
Question (number 
of responses)
Yes (n = 78) No (n = 40) Unsure (n = 92)
Q3: What is your 
age? (n = 224)
Mean 46.6 (range 20–74) 44.1 (range 19–73) 44.3 (range 19–77) –
Q4: What is your 
sex? (n = 210)
Male 32 (41.0%) 16 (40.0%) 26 (28.3%) Baseline
Female 46 (59.0%) 24 (60.0%) 66 (71.7%) 0.177a
Q5: Diagnosis? 
(n = 208)
Crohn's disease 29 (37.2%) 19 (50.0%) 45 (48.9%) Baseline
Ulcerative colitis 44 (56.4%) 19 (50.0%) 45 (48.9%) 0.197a
Other 5 (6.4%) 0 (0.0%) 2 (2.2%) 0.04a
Q6: Average time 
with the disease in 
years? (n = 209)
Mean 13.4 (range 
1.2–44.5)
14.1 (range 
0.1–52.7)
11.0 (range 
1.2–46.3)
–
Q7: Do you smoke? 
(n = 210)
Yes 2 (2.6%) 2 (5.0%) 9 (9.8%) 0.138a
Q9: Are any of your 
medications taken 
rectally? (n = 207)
Yes 17 (21.8%) 8 (20.5%) 18 (20.0%) 0.916a
Q10: Have you had 
surgery to the large 
bowel? (n = 208)
Yes 21 (27.3%) 9 (23.1%) 22 (23.9%) 0.679a
Q11: Are you 
awaiting surgery? 
(n = 208)
Yes 0 (0.0%) 0 (0.0%) 2 (2.2%) –
Q12: Are you 
considering surgery 
due to your symp-
toms? (n = 207)
Yes 10 (12.8%) 3 (7.9%) 5 (5.5%) 0.167a
Q13: Do you feel 
your symptoms are 
well controlled? 
(n = 197)
Yes 40 (52.6%) 24 (61.5%) 45 (54.9%) Baseline
No 15 (19.7%) 8 (20.5%) 11 (13.4%) 0.545a
Unsure 21 (27.6%) 7 (18.0%) 26 (31.7%) 0.864a
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Table 2. Responses obtained by the faecal microbiota transplantation questionnaire split by 
acceptability of FMT (Q20) after the provision of information
 aValues marked with an asterisk (*) are those based on Fisher's exact test, remaining p values are obtained using the 
Chi squared test. To construct 2x2 tables the “no” and “unsure” values were added together for both tests. For chi-
square tests the values were compared to the baseline.
bValues on these columns are based on question 20.
Q20: Does FMT now sound acceptable to 
you?b
pa
Questions truncated, full questions in 
appendix (number of responses)
Yes (n = 105) No (n = 33) Unsure (n = 58)
Q15: Would you 
consider par-
ticipating in a trial? 
(n = 195)
Yes 67 (64.4%) 1 (3.0%) 9 (15.5%) <0.001
No 19 (18.3%) 30 (90.9%) 16 (27.6%)
Unsure 18 (17.3%) 2 (6.1%) 33 (56.9%
Q16: If the trial 
was successful, 
everyone in the 
control group 
would be offered 
a faecal rectal 
enema at the end 
of the trial; would 
you then partici-
pate? (n = 195)
Yes 83 (79.1%) 1 (3.1%) 18 (31.0%) 0.755
No 12 (11.4%) 26 (81.3%) 6 (10.3%)
Unsure 10 (9.5%) 5 (15.6%) 34 (58.6%)
Q17: How many 
enemas would 
be acceptable? 
(n = 191)
It will never be 
acceptable
3 (2.9%) 21 (65.6%) 6 (11.1%) Baseline
Only one 8 (7.6%) 5 (15.6%) 6 (11.1%) Test for trend 
<0.001One a day for two 
days
6 (5.7%) 2 (6.3%) 5 (9.3%)
One a day for 
three days
4 (3.8%) 0 (0.0%) 6 (11.1%)
One a day for four 
days
1 (1.0%) 0 (0.0%) 0 (0.0%)
One a day for five 
days
14 (13.3%) 0 (0.0%) 5 (9.3%)
One a day for ten 
days
4 (3.8%) 0 (0.0%) 3 (5.6%)
As many as is 
needed
65 (61.9%) 4 (12.5%) 23 (42.6%)
Q18: Which donor 
would be more 
acceptable to you? 
(n = 187)
Partner 15 (14.6%) 8 (29.6%) 12 (21.1%) Baseline
Blood relatives 2 (1.9%) 3 (11.1%) 2 (3.51%) 0.681*
Anonymous donor, 
anyone who 
has the largest 
variation in their 
bowel biology 
(largest number of 
different types of 
bacteria)
86 (83.5%) 16 (59.3%) 43 (75.4%) 0.09*
Q19: Would you be 
happy to receive 
five faecal rectal 
enemas, one a 
day for five days? 
(n = 196)
Yes 80 (76.2%) 1 (3.0%) 8 (13.8%) 0.01
No 9 (8.6%) 28 (84.9%) 3 (5.2%)
Unsure 16 (15.2%) 4 (12.1%) 47 (81.0%)
Page 6 of 23
Palmer et al., Cogent Medicine (2016), 3: 1233685
http://dx.doi.org/10.1080/2331205X.2016.1233685
3. Results
224 responses were received from members of the CCUK, Table 1, with a response rate of 25%. Of 
those who reported demographic information 36.2% (n  =  81) of the respondents were male. The 
overall age range of individuals taking part was 19–77 years with a mean value of 45.1 years. This 
mean and age range was similar for men (47.7, range 21–77) and women (43.7, range 19–77). Of all 
the individuals who reported a diagnosis 51.9% (n = 108) were ulcerative colitis suffers, 44.7% (n = 93) 
were diagnosed with Crohn’s disease with the remainder reporting duel or mixed pathology.
Of the patient characteristics investigated, there was no evidence that taking medication rectally, 
having had surgery to the large bowel, and considering surgery due to symptoms were associated 
with the acceptability of FMT prior to the provision of information, Table 1. There was also no evi-
dence of association between how people viewed their illness (Q21) and their acceptability of FMT. 
For simplicity these results have not been reported.
Regarding numbers of stool transplants and source of stool, Table 2, respondents stated they 
would prefer, as many enemas as needed is the preferred option (test for trend p = < 0.001). An 
anonymous donor with the largest variation in their bowel biology was the most commonly chosen 
donor (77.5%, n = 145, p = 0.09). 18.7% (n = 35) stated they would prefer their partner to be the do-
nor, the preferred donor was not associated with subsequent response to Q20, the second time 
participants were asked about the acceptability of FMT.
On being asked for the first time does FMT sound acceptable 37.1% (n = 78, 41.0% of these being 
male) of respondents agreed with the statement that FMT sounded acceptable, with the remainder 
answering no (n = 40) or unsure (n = 92). The number of respondents answering “yes” to this ques-
tion increased to 105 (McNemar’s test p-value = < 0.001, Table 3) after they had answered questions 
examining the process of FMT (53.6%, n = 105, 59.7% of these being male).
4. Discussion
4.1. Main findings
This is the largest study identified that has examined the thoughts and attitudes of colitis sufferers 
on the acceptability of FMT. The study has identified that a large proportion of IBD sufferers consider 
FMT an acceptable treatment and that this acceptance increases when detailed information on the 
nature and purpose of the procedure is given.
Many FMT studies only give transplants where the recipient is related to the donor. Whether it is 
assumed by these studies that this would be more acceptable to patients is unclear. Studies have 
demonstrated that an unrelated donor (such as a spouse) may have a greater success in FMT than a 
blood related donor, possibly due to greater variability in microbiota (Gough, Shaikh, & Manges, 
2011). This study demonstrates that over 75% of the study population would prefer a donor who has 
Table 3. McNemar’s test comparing pre (Q14) and post (Q20) education
 Notes: There is strong evidence against the null hypothesis of the changes in response being equally likely to fall in 
either direction using McNemar’s test (p < 0.001).
Q20: Knowing what you know now; does FMT 
(taking stool (poo) from a healthy individual, 
mixing a sample (about an egg cup full) with 
water and giving it to you as a rectal enema) 
sound acceptable to you? (n = 196)
Q 14: Does FMT sound acceptable to you? (n = 210) Yes No Total
Yes 69 7 76
No 36 84 120
Total 105 91 196
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the greatest microbiota variability and are not concerned with the donors’ relationship status to 
them. Only 18% of respondents were found to prefer their partner as their ideal donor.
Since this study took place, an oral capsulized frozen form of FMT has been developed (Youngster 
et al., 2014). This procedure may be more acceptable to colitis sufferers as it is commonly given in 
double coated white capsules. This procedure may also become lower risk, easier to administer and 
cheaper compared to the current nasal-jejunum, colonoscopy or enema routes as these currently 
require much planning and liaison with microbiology laboratories for effective transplantation.
IBD is a debilitating disease which is increasing in prevalence and putting an increasing burden on 
health care resources. FMT is acceptable to the majority of colitis sufferers once the purpose of the 
procedure and the effect on the body has been explained. If the evidence from the awaited RCTs 
agrees with the reported Canadian study (Moayyedi et al., 2015) in that FMT could be an effective 
treatment for colitis sufferers, then adoption should be encouraged as it may provide a long-term 
resolution of symptoms.
4.2. What is already known on this topic
Only two studies were identified whose purpose was to explore patient attitudes towards FMT in ul-
cerative colitis (Kahn et al., 2013) or C. difficile infection (Zipursky, Sidorsky, Freedman, Sidorsky, & 
Kirkland, 2012). The findings from the present study are broadly in keeping with these studies in that 
the majority of individuals would accept FMT as a treatment option, once it is explained to them. 
However the present study found that acceptability of FMT rose sharply from 37.1% to 53.6% when 
precise information about the procedure is given.
4.3. What this study adds
This study demonstrates that patient acceptability and consent to FMT can be significantly increased 
provided a detailed explanation is given as to the reasons for using FMT and what it involves.
4.4. Limitations of this study
For ease the CCUK were approached to e-mail their members, but we recognise that the member-
ship of CCUK is not necessarily representative of all colitis sufferers. Individuals who were proactive 
about finding more information about their disease are likely to be members of this charity. Such 
individuals may be more likely to complete an unsolicited questionnaire from CCUK and may be 
more open to novel forms of therapy.
While the respondents to this survey were people suffering from IBD in the South West of England 
and South East Wales, it is believed that the results can be generalized to Northern European and 
North American populations where acceptability studies have been performed ( Kahn et al., 2013).
The response rate to this survey was low, unfortunately we have no information on the non-re-
sponders in terms of age, sex or area so we are unable to assess if there is any non-response bias.
While the survey had been based on the questions noted in other surveys for ulcerative colitis 
patients and was piloted amongst a small group of individuals, the questionnaire was not fully vali-
dated. However, the resultant findings are consistent with similar studies.
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